(BOSTON) – CARB-X is awarding up to US$2.42 million to Clarametyx Biosciences, based in Columbus, Ohio, USA, to develop a new treatment for serious bacterial biofilm infections, including those such as pneumonia caused by antibiotic-resistant ESKAPE pathogens and polymicrobial biofilms.  Clarametyx will be eligible for an additional $11.85 million in non-dilutive funding from CARB-X if project milestones are met, subject to available funds. Clarametyx’s pioneering therapy, CMTX-101, is a monoclonal antibody designed to rapidly collapse bacterial biofilms – protective shields that coat bacterial pathogens and help make them resistant to the effects of antibiotics and immune response.  CMTX-101 targets a region of DNABII binding proteins that are essentially identical across all pathogenic bacteria. Bacterial DNABII proteins stabilize and maintain the integrity of bacterial biofilms. Precisely targeting this region on the DNABII proteins rapidly collapses biofilms, rendering the bacteria more vulnerable to the effects of antibiotics and the immune system.

 

Credit: iStock, HRAUN

Read more CARB-X…